Traded Mar 27, 2026 · Filed Mar 30, 2026
A Lenz Therapeutics director paid $50K out of pocket for Lenz Therapeutics shares. 2 other people at Lenz Therapeutics bought some too, in the same month.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market purchase
Code P — open-market or private purchase
~$49,890
Shares × reported transaction price
$25K–$100K
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
3 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
3 days after results of Mar 24, 2026, 45 days before results of May 11, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
Traded Mar 27 · filed 3 days later
The CEO of Lenz Therapeutics paid $251K out of pocket for Lenz Therapeutics shares. 2 other people at Lenz Therapeutics bought some too, in the same month. The Lenz Therapeutics shares held grew by 57%.
Traded Mar 27 · filed 3 days later
The CFO of Lenz Therapeutics paid $64K out of pocket for Lenz Therapeutics shares. 2 other people at Lenz Therapeutics bought some too, in the same month. The Lenz Therapeutics shares held grew by 139%.
Traded Jan 2 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.